March 28, 2018 / 11:31 AM / 8 months ago

BRIEF-Edge Therapeutics Provides Update Following Interim Analysis

March 28 (Reuters) - Edge Therapeutics Inc:

* EDGE THERAPEUTICS PROVIDES UPDATE FOLLOWING INTERIM ANALYSIS OF PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE

* EDGE THERAPEUTICS INC - STUDY UNLIKELY TO ACHIEVE PRIMARY EFFICACY ENDPOINT; DMC RECOMMENDS DISCONTINUATION OF STUDY

* EDGE THERAPEUTICS INC - NO UNEXPECTED SAFETY FINDINGS IN STUDY

* EDGE THERAPEUTICS INC - EDGE TO REDUCE COSTS AND EVALUATE NEXT STEPS

* EDGE THERAPEUTICS - PHASE 3 STUDY OF EG-1962 SHOWED LOW PROBABILITY OF ACHIEVING STATISTICALLY-SIGNIFICANT DIFFERENCE VERSUS STANDARD OF CARE

* EDGE THERAPEUTICS - DATA MONITORING COMMITTEE RECOMMENDED STUDY BE STOPPED BASED ON CONCLUSION THAT STUDY HAS LOW PROBABILITY OF MEETING PRIMARY ENDPOINT

* EDGE THERAPEUTICS - ANTICIPATES IN NEAR TERM REDUCING SCOPE OF OPERATIONS, INCLUDING SIZE OF WORKFORCE, IN ORDER TO PRESERVE CASH RESOURCES

* EDGE THERAPEUTICS INC - HAS DECIDED TO DISCONTINUE NEWTON 2 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below